WuXi’s New Unit Joins Race For Drug Innovation In China
This article was originally published in PharmAsia News
WuXi is opening up its service platform, manufacturing capacity and pockets, aiming to develop global innovations in China faster and cost-effectively. The strategy may draw on a template of a joint venture with MedImmune and a contract manufacturing deal for Ambrx already in place.
You may also be interested in...
US-based, China-focused CANbridge moves into cholestatic liver disease and enzyme replacement therapy via two deals. Plus deals involving LegoChem, TransThera, Morepen, Daiichi Sankyo, Geneseeq, Innocare, Biosplice, Sirnaomics and Walvax.
As the US responds to calls to waive intellectual property rights related to COVID-19 vaccines, China is already moving ahead with some of its own mRNA candidates.
Amid controversy over vaccines protection efficacy, China overhauls its disease control system with a brand-new agency to oversee disease control and prevention measures.